



The Drug Utilization Review (DUR) Board Reviewed  
the Following New Drugs/Classes on  
January 17, 2024

| <b>Therapeutic Class</b>                      | <b>Drug Name</b>                          | <b>DURB Recommendation*</b> |
|---|---|-----------------------------|
| <b>Duchenne Muscular Dystrophy Treatments</b> |   |                             |
|   | <i>Elevidys (Intravenous) Suspension</i>  | P/PA on PADL                |
| <b>Hypoglycemics, SGLT2</b>                   |   |                             |
|   | <i>Inpefa (Oral) Tablet</i>               | NP/PA                       |
| <b>Hemophilia Treatment</b>                   |   |                             |
|   | <i>Roctavian (Intravenous) Suspension</i> | NP/PA on PADL               |
| <b>Estrogen Agents, Oral/Transdermal</b>      |   |                             |
|   | <i>Veozah (Oral) Tablet</i>               | NP/PA                       |
| <b>Antimigraine Agents, Other</b>             |   |                             |
|   | <i>Zavzpret (Nasal) Spray</i>             | NP/PA                       |

\*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;  
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'  
Administered Drug List